Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595488 · ClinicalTrials.gov registry record · Phase 2
Dupilumab for Aspirin-exacerbated Respiratory Disease
A Phase 2 study of Aspirin-exacerbated Respiratory Disease, sponsored by Rochester General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT03595488 is a Phase 2 study of Aspirin-exacerbated Respiratory Disease that has completed, run by Rochester General Hospital. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03595488, a Phase 2 study of Aspirin-exacerbated Respiratory Disease, has completed, sponsored by Rochester General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
New York
- Rochester Regional Health - Allergy/Immunology - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03595488
The ClinicalTrials.gov registry entry for NCT03595488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rochester General Hospital, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aspirin-exacerbated Respiratory Disease appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT03595488 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03595488 about?
NCT03595488 is a clinical study titled "Dupilumab for Aspirin-exacerbated Respiratory Disease". Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.
What is the current status of trial NCT03595488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-09-05. Estimated completion is 2019-12-11.
What conditions does trial NCT03595488 study?
This clinical trial studies the following conditions: Aspirin-exacerbated Respiratory Disease.
What interventions are being tested in trial NCT03595488?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03595488?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03595488 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aspirin-exacerbated Respiratory Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.